Document is current
Any future updates will be listed below
-
Authors
Mezquita, Laura https://orcid.org/0000-0003-0936-7338
Vicente-Herrero, Mª Teófila
Cruz, Patricia
de la Torre, Mª Victoria Ramírez Íñiguez
Hidalgo-Coloma, Julia
García, Luisa Capdevila
Gallego, Oscar
Calvo, Aitana
Martínez, Katerine
Pérez-Altozano, Javier
Molina, Raquel
García-Pardo, Miguel
Gutiérrez-Sainz, Laura
Moreno-Atahonero, Elena
Oré-Arce, Martín
Serrano, César
Terradillos-García, María Jesús
Valero, María Rosario
Reinoso-Barbero, Luís
Rodríguez, César A.
Calvo-Cerrada, Beatriz
,
-
Funding
Funding for this research was provided by:
ISCIII (JR20/00019, FIS 2021 - PI21/01653, FIS 2024 - PI24/00982)
Ayuda SEOM - Juan Rodés 2020
EURATOM Horizon 2020 (900009 — NFRP-2019-2020)
Programa CRIS Contra el Cáncer Talento Médico Investigador 2024
- License Information
-
More Information
Article History
Received: 6 June 2025
Accepted: 15 August 2025
First Online: 16 September 2025
Declarations
:
: LM: No other conflicts of interest related to this work have been reported. Outside the scope of this work, LM has participated in the following activities: Consulting/Advisory Role: Roche, Takeda, Janssen, MSD; Speakers’ Bureau: Bristol Myers Squibb, AstraZeneca, Roche, Takeda, Janssen, Radonova, Daiicki Sankyo; Research Funding: Inivata, AstraZeneca, Gilead; Travel, Accommodations, and Expenses: Bristol Myers Squibb, Roche, AstraZeneca, Takeda, Janssen. MTVH: No other conflicts of interest directly related to the present study have been disclosed. PC: No other conflicts of interest directly related to the present study have been disclosed. MVRI: No other conflicts of interest directly related to the present study have been disclosed. JHC: No other conflicts of interest directly related to the present study have been disclosed. LCG: No other conflicts of interest directly related to the present study have been disclosed. OG: No other conflicts of interest directly related to the present study have been disclosed. AC: No other conflicts of interest directly related to the present study have been disclosed. KM: Employee of AstraZeneca. No other conflicts of interest directly related to the present study have been disclosed. JPA: No other conflicts of interest directly related to the present study have been disclosed. RM: No other conflicts of interest directly related to the present study have been disclosed. MGP: Travel, Accommodations, Expenses: Roche, AstraZeneca, Takeda, Pfizer. LGS: No other conflicts of interest directly related to the present study have been disclosed. Outside the scope of this work, LGS has participated in the following activities: Consulting/Advisory Role: Roche; Travel, Accommodations, and Expenses: Roche, Pfizer, AstraZeneca, Takeda, Janssen. EM: No other conflicts of interest directly related to the present study have been disclosed. MOA: No other conflicts of interest directly related to the present study have been disclosed. CS: No other conflicts of interest directly related to the present study have been disclosed. MJT: No other conflicts of interest directly related to the present study have been disclosed. MRV: No other conflicts of interest directly related to the present study have been disclosed. LRB: No other conflicts of interest directly related to the present study have been disclosed. CAR: No other conflicts of interest directly related to the present study have been disclosed. Outside the scope of this work, CAR has participated in the following activities: Consulting/Advisory Role: Roche, Menarini, MSD, Astra-Zeneca, Daiichi-Sankyo. Speakers’ Bureau: Roche, Novartis, Astra-Zeneca, Daiichi-Sankyo, MSD. BCC: No other conflicts of interest directly related to the present study have been disclosed.
: For this type of study, consent is not required.
: This article does not contain any studies with human participants performed by any of the authors.
